Silence Therapeutics Stock Rises on Cantor Fitzgerald Overweight Rating

By EC Assets · Published 24 June 2026

Silence Therapeutics stock has increased following analyst coverage initiation by Cantor Fitzgerald. The investment firm assigned an overweight rating to the company. Silence Therapeutics' shares are currently trading at $7.27. Cantor Fitzgerald initiated coverage on Silence Therapeutics on Tuesday. Prakhar Agrawal, an analyst at Cantor Fitzgerald, is leading the coverage. The firm’s initiation highlights growing interest in Silence Therapeutics. Silence Therapeutics is preparing to release results from a Phase 2 trial. The trial involves a drug for polycythemia vera. Preliminary data from this trial is anticipated in August 2026. FactSet data indicates an average rating of overweight for Silence Therapeutics. The mean price target from analysts polled by FactSet is $31.20. The company's market capitalization is approximately $343 million. This article is intended for informational purposes only. It does not constitute investment advice.